By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Upper respiratory combinations > Hycodan > Hycodan Pregnancy and Breastfeeding Warnings
Upper respiratory combinations

Homatropine / hydrocodone Pregnancy and Breastfeeding Warnings

Contents
Hycodan Pregnancy Warnings Hycodan Breastfeeding Warnings

Hycodan Pregnancy Warnings

Animal studies have not been conducted with this combination product, and there are no adequate and well-controlled studies in pregnant women.

Hydrocodone:
Animal studies with subcutaneous hydrocodone have shown teratogenicity when given during organogenesis at doses approximately 70 times the maximum recommended human dose (MRHD). Opioids cross the placenta and may produce respiratory depression and psycho-physiologic effects in neonates. Babies born to mothers taking opioids regularly during pregnancy may become physically dependent. Opioids can prolong labor by temporarily reducing the strength, duration, and frequency of uterine contractions, however this effect is not consistent and may be offset by an increased rate of cervical dilation, which tends to shorten labor. Opioids given to mothers shortly before delivery may produce some degree of respiratory depression in the newborn, especially if high doses are used. Chronic use of opioids may reduce fertility in males and females of reproductive potential; it is unknown if these effects are reversible.

Homatropine: Animal studies are not available.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

Use is not recommended, including during or immediately prior to labor

US FDA pregnancy category: Not assigned

Comments:
-Prolonged use of opioids during pregnancy may cause neonatal withdrawal syndrome and physical dependence in the neonate.
-Neonatal withdrawal syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea, and failure to gain weight.
-The onset, duration, and severity of neonatal withdrawal syndrome vary with the specific opioid used, duration of use, timing and amount of last maternal use, and the newborn's rate of drug elimination.
-Observe newborns for symptoms of neonatal withdrawal syndrome and manage appropriately.
-An opioid antagonist (e.g. naloxone) should be available for reversal of opioid-induced respiratory depression in the neonate.
-Monitor neonates exposed to opioids during labor for excess sedation and respiratory depression.
-Advise women of the risk of neonatal withdrawal syndrome and ensure that appropriate treatment will be available.

See references

Hycodan Breastfeeding Warnings

Use is not recommended.

Excreted into human milk: Unknown (homatropine); Yes (hydrocodone)

Comments:
-This drug has a potential for serious adverse reactions, including excess sedation, respiratory depression, and death.
-Breastfed infants should be closely monitored for excess sedation, respiratory depression, and irritability.
-Withdrawal symptoms can occur in breastfed infants when maternal opioids are stopped or breastfeeding is stopped.

Hydrocodone: Case reports have shown variable hydrocodone and hydromorphone (an active metabolite) levels in breast milk with use of immediate release hydrocodone to nursing mothers in the early postpartum period with relative infant doses of hydrocodone ranging between 1.4 and 3.7%. There are case reports of excessive sedation and respiratory depression in breastfed infants exposed to hydrocodone.

Homatropine: No information is currently available on homatropine's presence in breast milk or effects on lactation. Published literature suggests homatropine may decrease milk production due to its anticholinergic effect.

See references

Share this Article
Latest News
Medical News

Obesity, unhealthy lifestyles may cause heart to age by 5–45 years

May 08, 2025
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Heart disease: Just 3 minutes of 'incidental activity' may lower...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by